Literature DB >> 2459319

Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance.

P I Thompson1, J Nixon, V J Harvey.   

Abstract

Thirty-six patients with apparent stage I nonseminomatous germ cell tumor (NSGCT) of the testis were treated by inguinal orchidectomy and intensive follow-up only. Assessment included measurement of serum alpha fetoprotein (alpha FP) and beta human chorionic gonadotropin (beta HCG) (tumor markers) and chest x-ray monthly for 1 year, then twice monthly for 1 year, with computed tomographic (CT) scans of abdomen and chest repeated three times monthly for the first year and six times monthly for the second year. Median follow-up was 36 months (range, 14 to 92 months). Relapse occurred in 12 patients (33.3%) at a median of 7 months (range, 2 to 28 months). Elevated markers were of limited importance in relapse detection, confirming the need for close clinical and radiological follow-up. Of nine histological factors examined in the primary tumor only the presence of lymphatic invasion was associated with a significantly higher relapse rate. All patients were treated at relapse with cisplatin-based chemotherapy. Four underwent surgery in addition, two before and two after chemotherapy. Eleven were rendered disease-free, but four had a second relapse. One patient has died, one is alive with disease, and ten are disease-free. Chemotherapy failed to cure six patients who had relapsed but bulk of disease was not a factor. Despite the good overall result reported here, optimal postorchidectomy management of apparent stage I disease remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459319     DOI: 10.1200/JCO.1988.6.10.1597

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

2.  Prognostic features and markers for testicular cancer management.

Authors:  Eddy S Leman; Mark L Gonzalgo
Journal:  Indian J Urol       Date:  2010 Jan-Mar

3.  Imaging of testicular germ cell tumours.

Authors:  P U Dalal; S A Sohaib; R Huddart
Journal:  Cancer Imaging       Date:  2006-09-07       Impact factor: 3.909

Review 4.  Global incidence and outcome of testicular cancer.

Authors:  Thurkaa Shanmugalingam; Aspasia Soultati; Simon Chowdhury; Sarah Rudman; Mieke Van Hemelrijck
Journal:  Clin Epidemiol       Date:  2013-10-17       Impact factor: 4.790

5.  How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources?

Authors:  S D Fosså; A B Jacobsen; N Aass; A Heilo; A E Stenwig; O Kummen; N B Johannessen; G Waaler; P Ogreid; L Borge
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

Review 6.  Lymph node imaging in testicular cancer.

Authors:  Graham R Hale; Seth Teplitsky; Hong Truong; Samuel A Gold; Jonathan B Bloom; Piyush K Agarwal
Journal:  Transl Androl Urol       Date:  2018-10

Review 7.  Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.

Authors:  Joost M Blok; Ilse Pluim; Gedske Daugaard; Thomas Wagner; Katarzyna Jóźwiak; Erica A Wilthagen; Leendert H J Looijenga; Richard P Meijer; J L H Ruud Bosch; Simon Horenblas
Journal:  BJU Int       Date:  2020-01-08       Impact factor: 5.588

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.